BULLETIN OF THE
Note
KOREAN CHEMICAL SOCIETY
References
1
2
3
4
. I. Bab, A. Zimmer, Br. J. Pharmacol. 2008, 153, 182.
. G. D. Roodman, Exp. Hematol. 1999, 27, 1229.
. S. L. Teitelbaum, Science 2000, 289, 1504.
. T. D. Rachner, S. Khosla, L. C. Hofbauer, Lancet 2011,
3
77, 1276.
5
6
7
8
9
. S. Palacios, J. L. Neyro, S. Fernández de Cabo, J. Chaves,
J. Rejas, Climacteric 2014, 17, 60.
. S. Khosla, L. C. Hofbauer, Lancet Diabetes Endocrinol.
Figure 4. Effect of SC0030 on the translational expression of an
osteoclast-specific transcription factor, NFATc1. BMMs were
pretreated with vehicle (0.1% DMSO) or TRPV1 antagonist
SC0030 (3 μg/mL) for 1 h prior to RANKL (10 ng/mL) and M-
CSF (30 ng/mL) stimulation at the indicated time. β-Actin was
used as the internal control.
2
017, 5, 898.
. S. F. Vondracek, P. Minne, M. T. McDermott, Clin. Interv.
Aging 2008, 3, 315.
. J. F. Charles, A. O. Aliprantis, Trends Mol. Med. 2014,
2
0, 449.
. N. Renema, B. Navet, M. F. Heymann, F. Lezot,
D. Heymann, Biosci. Rep. 2016, 36, e00366.
0. C. A. Nelson, J. T. Warren, M. W. H. Wang,
end stage of osteoclast differentiation, the translational
expression of NFATc1 was downregulated at the late stage,
and then it disappeared at the end stage of osteoclast differ-
entiation. Consequently, SC0030 suppressed the osteoclast
differentiation by inhibiting the protein expression of
NFATc1, which is a key element in the osteoclast formation
process.
1
S. L. Teitelbaum, D. H. Fremont, Structure 2012, 20, 1971.
11. C. Liu, T. S. Walter, P. Huang, S. Zhang, X. Zhu, Y. Wu,
L. R. Wedderburn, P. Tang, R. J. Owens, D. I. Stuart, J. Ren,
B. Gao, J. Immunol. 2010, 184, 6910.
2. J. H. Park, N. K. Lee, S. Y. Lee, Mol. Cells 2017, 40, 706.
3. H. Takayanagi, S. Kim, T. Koga, H. Nishina, M. Isshiki,
H. Yoshida, A. Saiura, M. Isobe, T. Yokochi, J. I. Inoue,
E. F. Wagner, T. W. Mak, T. Kodama, T. Taniguchi, Dev.
Biol. 2002, 3, 889.
1
1
In summary, osteoporosis is a pathological condition that
manifests the fracture and chronic pain. The management
of osteoporosis always remains complicated due to side
effects and inefficiency of current therapies. Antagonism of
TRPV1 by capsazepine was reported to prevent bone loss
in osteoporotic animal models such as ovariectomized rat.
Some studies also demonstrated that TRPV1 directly regu-
lates osteoclast differentiation both in vitro and in vivo.
Thus, TRPV1 antagonism might be useful for inhibition of
osteoclast differentiation related to osteoporosis. In this
study, we demonstrated that our TRPV1 antagonist
SC0030, which has a strong in vitro and in vivo TRPV1
inhibitory activity, led the inhibition of RANKL-mediated
osteoclast differentiation that is a main process of bone
resorption leading to bone loss in osteoporosis. SC0030
also inhibited the expression of NFATc1, a key down-
stream target of RANKL-RANK signaling pathway
involved in osteoclastogenesis. Additionally, SC0030 led
the inhibition of gene expressions such as DC-STAMP,
TRAP and cathepsin K which are the key regulators in
osteoclast differentiation. This study indicates that TRPV1
antagonist such as SC0030 would be beneficial to the pre-
vention of bone loss in osteoporosis.
1
4. J. Jules, J. W. Ashley, X. Feng, Expert Opin. Ther. Targets
2
010, 14, 923.
1
5. K. A. Mensah, C. T. Ritchlin, E. M. Schwarz, J. Cell. Phy-
siol. 2010, 223, 76.
16. M. J. Caterina, A. Leffler, A. B. Malmberg, W. J. Martin,
J. Trafton, K. R. Petersen-Zeitz, M. Koltzenburg,
A. I. Basbaum, D. Julius, Science 2000, 288, 306.
7. A. Engler, A. Aeschlimann, B. R. Simmen, B. A. Michel,
R. E. Gay, S. Gay, H. Sprott, Biochem. Biophys. Res.
Commun. 2007, 359, 884.
8. K. Gavenis, C. Schumacher, U. Schneider, J. Eisfeld,
J. Mollenhauer, B. Schmidt-Rohlfing, Mol. Cell. Biochem.
1
1
1
2
009, 321, 135.
9. F. Rossi, D. Siniscalco, L. Luongo, L. De Petrocellis,
G. Bellini, S. Petrosino, M. Torella, C. Santoro, B. Nobili,
S. Perrotta, V. Di Marzo, S. Maione, Bone 2009, 44, 476.
20. L. Pan, K. Song, F. Hu, W. Sun, I. Lee, Eur. J. Pharmacol.
2013, 715, 280.
21. S. P. H. Alexander, H. E. Benson, E. Faccenda, A. J. Pawson,
J. L. Sharman, W. A. Catterall, M. Spedding, J. A. Peters,
A. J. Harmar, C. Collaborators, Br. J. Pharmacol. 2013,
1
70, 1607.
2. A. I. Idris, E. Landao-Bassonga, S. H. Ralston, Bone 2010,
6, 1089.
2
2
4
Acknowledgments. This research was supported by the
National Research Foundation of Korea (NRF) funded by
the Ministry of Science, ICT & Future Planning (NRF-
3. Y. G. Suh, Y. S. Lee, K. H. Min, O. H. Park,
H. S. Seung, H. D. Kim, H. G. Park, J. Y. Choi, J. Lee,
S. W. Kang, U. T. Oh, J. Y. Koo, Y. H. Joo, S. Y. Kim,
J. K. Kim, Y. H. Park, Bioorg. Med. Chem. Lett. 2003,
2
019R1F1A1063304 & NRF-2018R1D1A1B07050581),
and Sunchon National University Research Fund in 2018
Grant number: 2018-0195).
1
3, 4389.
(
24. Y. G. Suh, Y. S. Lee, K. H. Min, O. H. Park, J. K. Kim,
H. S. Seung, S. Y. Seo, B. Y. Lee, Y. H. Nam, K. O. Lee,
H. D. Kim, H. G. Park, J. Lee, U. Oh, J. O. Lim, S. U. Kang,
M. J. Kil, J. Y. Koo, S. S. Shin, Y. H. Joo, J. K. Kim,
Supporting Information. Additional supporting informa-
tion is available in the online version of this article
Bull. Korean Chem. Soc. 2020
© 2020 Korean Chemical Society, Seoul & Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
www.bkcs.wiley-vch.de
3